Please try another search
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Name | Age | Since | Title |
---|---|---|---|
Edo Ronald De Kloet | - | - | Member of Scientific Advisory Board |
K. Ranga Rama Krishnan | 64 | - | Member of Scientific Advisory Board |
Florian Holsboer | - | - | Member of Scientific Advisory Board |
Ned H. Kalin | - | - | Member of Scientific Advisory Board |
Charles B. Nemeroff | 71 | - | Member of Scientific Advisory Board |
James N. Wilson | 77 | 1999 | Independent Chairman |
Bruce S. McEwen | - | - | Member of Scientific Advisory Board |
Joseph K. Belanoff | 64 | 1999 | Co-Founder, President, CEO & Director |
Kimberly Park | 57 | 2019 | Independent Director |
Gillian M. Cannon | 57 | 2020 | Independent Director |
Daniel N. Swisher | 58 | 2015 | Independent Director |
George Leonard Baker | 78 | 1999 | Independent Director |
David L. Mahoney | 67 | 2004 | Independent Director |
Gregg H. Alton | 55 | 2020 | Independent Director |
Joshua M. Murray | - | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review